WisdomTree BioRevolution Fund (WDNA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
WisdomTree BioRevolution Fund (WDNA) trades at $23.20 with AI Score 47/100 (Grade C). WisdomTree BioRevolution Fund (WDNA) is a non-diversified fund that seeks to track the investment results of an index designed to provide… Market cap: $3.02M, Sector: Financial services.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for WDNA: WDNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates WDNA against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
WDNA: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
WisdomTree BioRevolution Fund (WDNA) Financial Services Profile
WisdomTree BioRevolution Fund (WDNA) offers investors targeted exposure to global companies poised to benefit from advancements in genetics and biotechnology. Employing a representative sampling strategy, the fund aims to replicate the performance of its underlying index, providing a focused investment vehicle within the asset management sector for those seeking to capitalize on bio-revolution trends.
What Is the Investment Thesis for WDNA?
WDNA presents a focused investment opportunity for those seeking exposure to the rapidly evolving genetics and biotechnology landscape. The fund's representative sampling strategy offers an efficient way to track the performance of its underlying index, providing targeted access to companies expected to be significantly impacted by advancements in the sector. With a beta of 1.69, the fund demonstrates higher volatility compared to the broader market, which could lead to potentially higher returns. The absence of a dividend yield reflects the fund's focus on growth-oriented companies within the bio-revolution space. The key value driver is the continued innovation and adoption of genetic and biotechnological advancements across various industries. Upcoming catalysts include further breakthroughs in gene editing technologies and increased investment in personalized medicine, which could drive growth for companies within the fund's portfolio.
Based on FMP financials and quantitative analysis
WDNA Key Highlights
WDNA offers targeted exposure to the bio-revolution sector, focusing on companies expected to be significantly transformed by advancements in genetics and biotechnology.
- The fund employs a representative sampling strategy, aiming to replicate the risk and return characteristics of its underlying index.
- WDNA is a non-diversified fund, which may result in higher volatility compared to more broadly diversified investment options.
- The fund's beta of 1.69 indicates a higher sensitivity to market movements compared to the overall market.
- WDNA does not offer a dividend yield, reflecting its focus on growth-oriented companies within the bio-revolution space.
Who Are WDNA's Competitors?
WDNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BWET Breakwave Tanker Shipping ETF | $449.97 | +4.71% | $60.8M | 50 |
| IDKFF ThreeD Capital Inc. | $0.07 | +13.85% | $6.98M | 70 |
| ALTEX Firsthand Alternative Energy Fund | $12.93 | -1.90% | $8.98M | 82 |
| ALISR Calisa Acquisition Corp Right | $0.64 | +0.00% | 79 | |
| BCG Binah Capital Group, Inc. | $1.40 | +0.72% | $23.5M | 78 |
| EEA The European Equity Fund, Inc. | $11.15 | -0.59% | $74.7M | 67 |
| HNNA Hennessy Advisors, Inc. | $9.89 | -1.30% | $78.2M | 81 |
| ETHT ProShares - Ultra Ether ETF | $12.57 | +19.94% | $92.2M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are WDNA's Key Strengths?
Targeted exposure to the high-growth bio-revolution sector.
- Efficient tracking of its underlying index through representative sampling.
- WisdomTree's established brand and expertise in ETF management.
What Are WDNA's Weaknesses?
Non-diversified nature may lead to higher volatility.
- Reliance on the performance of a specific sector.
- Potential for higher expense ratios compared to broad-based ETFs.
What Could Drive WDNA Stock Higher?
Advancements in gene editing technologies, such as CRISPR-Cas9, leading to new therapeutic applications.
- Increasing investment in personalized medicine and targeted therapies.
- Expansion of biotechnology into agriculture and sustainable food production.
- Rising demand for biopharmaceuticals and innovative drug development.
What Are the Key Risks for WDNA?
Regulatory hurdles and changes in government policies impacting the biotechnology sector.
- Clinical trial failures and setbacks in drug development.
- Ethical concerns and public perception regarding gene editing and genetic engineering.
- Economic downturns affecting investment in research and development.
What Are the Growth Opportunities for WDNA?
- Increased Investment in Personalized Medicine: The growing trend towards personalized medicine, where treatments are tailored to an individual's genetic makeup, presents a significant growth opportunity for companies within WDNA's portfolio. As diagnostic tools become more sophisticated and affordable, the demand for personalized therapies is expected to increase, driving revenue growth for companies involved in gene sequencing, targeted drug development, and precision diagnostics. The personalized medicine market is projected to reach $2.4 trillion by 2030, offering substantial growth potential for WDNA's holdings.
- Advancements in Gene Editing Technologies: Gene editing technologies like CRISPR-Cas9 are revolutionizing the treatment of genetic diseases. Companies developing and commercializing gene editing therapies are poised for significant growth as these technologies become more refined and accessible. WDNA's exposure to companies in this space positions it to benefit from the increasing adoption of gene editing for treating a wide range of diseases, including cancer, inherited disorders, and infectious diseases. The gene editing market is expected to reach $11.7 billion by 2027.
- Expansion of Biotechnology into Agriculture: Biotechnology is increasingly being applied to agriculture to improve crop yields, enhance nutritional content, and develop pest-resistant varieties. Companies involved in agricultural biotechnology are experiencing strong growth as the demand for sustainable and efficient food production increases. WDNA's exposure to companies in this area allows it to capitalize on the growing adoption of biotechnology in agriculture, driven by the need to feed a growing global population and address climate change.
- Rising Demand for Biopharmaceuticals: The global biopharmaceutical market is experiencing robust growth, driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug development. Companies developing and manufacturing biopharmaceuticals are benefiting from strong demand for innovative therapies. WDNA's exposure to biopharmaceutical companies allows it to participate in the growth of this sector, driven by the increasing adoption of biologics for treating a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases.
- Growing Adoption of Digital Health Technologies: Digital health technologies, such as wearable sensors, telehealth platforms, and mobile health apps, are transforming healthcare delivery and improving patient outcomes. Companies developing and commercializing digital health solutions are experiencing rapid growth as healthcare providers and patients increasingly adopt these technologies. WDNA's exposure to companies in this space allows it to capitalize on the growing adoption of digital health, driven by the need to improve access to care, reduce healthcare costs, and enhance patient engagement.
What Are WDNA's Competitive Advantages?
- Specialized Focus: WDNA's focus on the bio-revolution sector provides a unique investment opportunity.
- Representative Sampling Strategy: The fund's approach offers efficient tracking of its underlying index.
- WisdomTree Brand: WisdomTree's reputation and expertise in ETF management provide a competitive advantage.
What Does WDNA Do?
WisdomTree BioRevolution Fund (WDNA) is a specialized, non-diversified exchange-traded fund (ETF) designed to capture the growth potential of companies at the forefront of the genetics and biotechnology revolution. The fund operates under a representative sampling strategy, which involves investing in a carefully selected subset of securities within its benchmark index. This approach aims to replicate the overall risk, return, and characteristics of the entire index, providing investors with a cost-effective and efficient way to access this dynamic sector. The fund focuses on companies that are expected to experience significant transformation due to advancements in genetics and biotechnology. By concentrating its investments in this specific area, WDNA offers a targeted investment vehicle for those seeking exposure to the potential upside of the bio-revolution. The fund's non-diversified nature means that it may be subject to greater volatility than more broadly diversified funds, but it also offers the potential for higher returns if the targeted sector performs well. WisdomTree, as the fund's sponsor, brings its expertise in developing and managing innovative ETFs to the bio-revolution space.
What Products and Services Does WDNA Offer?
- Invests in equity securities of exchange-listed companies globally.
- Focuses on companies expected to be significantly transformed by advancements in genetics and biotechnology.
- Employs a representative sampling strategy to track its index.
- Offers investors exposure to the bio-revolution sector.
- Operates as a non-diversified fund.
- Aims to replicate the risk, return, and other characteristics of its underlying index.
How Does WDNA Make Money?
- Generates revenue through management fees charged to investors.
- Tracks a specific index focused on companies in the bio-revolution sector.
- Utilizes a representative sampling strategy to achieve its investment objective.
What Industry Does WDNA Operate In?
The asset management industry is undergoing significant transformation, driven by technological advancements, changing investor preferences, and increasing regulatory scrutiny. ETFs like WDNA are gaining popularity due to their transparency, cost-effectiveness, and targeted investment strategies. The bio-revolution sector is experiencing rapid growth, fueled by breakthroughs in genetics, biotechnology, and personalized medicine. WDNA competes with other specialized ETFs and mutual funds that focus on healthcare, biotechnology, and genomics. The competitive landscape includes both broad-based healthcare funds and more narrowly focused funds targeting specific areas within the bio-revolution space. These funds include BWET, DESK, EGLE, FGSI, and JETD.
Who Are WDNA's Key Customers?
- Individual investors seeking exposure to the bio-revolution sector.
- Institutional investors looking for targeted investment strategies.
- Financial advisors seeking specialized investment products for their clients.
WisdomTree BioRevolution Fund (WDNA) Valuation Context
Valued at $3.02M, WDNA is classified as a micro-cap stock. Relative to its peer group, WDNA's quantitative score of 47/100 is below the peer average of 72/100.
Key Financial Metrics
Return on equity for WisdomTree BioRevolution Fund stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. WDNA trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
WDNA Financials
Bull Case vs Bear Case
Bull Case
- Targeted exposure to the high-growth bio-revolution sector.
- Efficient tracking of its underlying index through representative sampling.
- WisdomTree's established brand and expertise in ETF management.
- Ongoing: Advancements in gene editing technologies, such as CRISPR-Cas9, leading to new therapeutic applications.
Bear Case
- Non-diversified nature may lead to higher volatility.
- Reliance on the performance of a specific sector.
- Potential for higher expense ratios compared to broad-based ETFs.
- Potential: Regulatory hurdles and changes in government policies impacting the biotechnology sector.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
WDNA Latest News
No recent news available for WDNA.
WDNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for WDNA.
Price Targets
Wall Street price target analysis for WDNA.
WDNA MoonshotScore
What does this score mean?
The MoonshotScore rates WDNA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
WDNA Financial Services Stock FAQ
What does the AI Score mean for WDNA?
WDNA holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. WisdomTree BioRevolution Fund (WDNA) is a non-diversified fund that seeks to track the investment results of an index designed to provide exposure to companies expected to be significantly …
What does WisdomTree BioRevolution Fund do?
WisdomTree BioRevolution Fund (WDNA) is a non-diversified exchange-traded fund (ETF) that seeks to track the investment results of an index designed to provide exposure to companies expected to be significantly transformed by advancements in genetics and biotechnology.
What are the main risks for WDNA?
As a non-diversified fund focused on the bio-revolution sector, WDNA faces several risks. Regulatory changes impacting the biotechnology and healthcare industries could significantly affect the performance of companies within the fund's portfolio. Clinical trial failures and setbacks in drug development are inherent risks in the biotechnology sector.
What are the key factors to evaluate for WDNA?
WisdomTree BioRevolution Fund (WDNA) holds an AI score of 47/100 (low). WDNA presents a focused investment opportunity for those seeking exposure to the rapidly evolving genetics and biotechnology landscape. Not financial advice.
How frequently does WDNA data refresh on this page?
WDNA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven WDNA's recent stock price performance?
WisdomTree BioRevolution Fund (WDNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Targeted exposure to the high-growth bio-revolution sector. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider WDNA overvalued or undervalued right now?
WisdomTree BioRevolution Fund (WDNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research WDNA before investing?
Before investing in WisdomTree BioRevolution Fund (WDNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding WDNA to a portfolio?
Key strength of WisdomTree BioRevolution Fund (WDNA): Targeted exposure to the high-growth bio-revolution sector. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and general knowledge of the financial services sector. AI analysis is pending for WDNA, which may provide additional insights.